308-nm excimer laser in the treatment of a localized recalcitrant form of perioral dermatitis: Case report

Catarina Queirós,Paulo Filipe,Luís Uva

doi:10.7241/ourd.2022e.5

Abstract

In the last two decades, 308-nm excimer laser has been increasingly recognized as a therapeutic alternative for several dermatological conditions, being currently FDA approved for the treatment of localized vitiligo and moderately severe localized psoriasis unresponsive to topical treatments. We describe the case of a 17-year-old with a recalcitrant form of dermatitis occupying the entire perioral region, previously unresponsive to several treatments, who was treated with 308-nm excimer laser with an excellent result. 308-nm monochromatic excimer laser has several advantages over other types of phototherapy, including lower UV dose exposure, shorter courses of therapy and a better sparing of adjacent tissue. Although infrequently used, 308-nm excimer laser certainly has a vast potential in Dermatology, particularly regarding recalcitrant and localized inflammatory conditions, such as the one we present.

Highlights

In the last two decades, 308-nm excimer laser has been increasingly recognized as a therapeutic alternative for several dermatological conditions [1,2]
It is currently FDA approved only for the treatment of localized vitiligo and moderately severe localized psoriasis unresponsive to topical treatments, case reports have substantiated its use for localized severe atopic eczema, alopecia areata, cutaneous T-cell lymphoma, localized scleroderma, nail psoriasis and granuloma annulare, among other entities [1,3]
We describe the case of a 17-year-old girl, Fitzpatrick skin type II, with no past relevant medical history, who was brought to our Dermatology Department complaining of erythema, desquamation, itching and a burning sensation in the perioral region for the last two months (Fig. 1)

Summary

INTRODUCTION

In the last two decades, 308-nm excimer laser has been increasingly recognized as a therapeutic alternative for several dermatological conditions [1,2]. It is currently FDA approved only for the treatment of localized vitiligo and moderately severe localized psoriasis unresponsive to topical treatments, case reports have substantiated its use for localized severe atopic eczema, alopecia areata, cutaneous T-cell lymphoma, localized scleroderma, nail psoriasis and granuloma annulare, among other entities [1,3]

CASE REPORT

DISCUSSION